Compounds like folate receptor 1-T-cell bsAb (FOLR1-TCB) and protease-activated anti-FOLR1-TCB (Prot-FOLR1-TCB) have shown potent preclinical activity in ovarian cancer models, with reduced systemic toxicity [146]. The gene discussed is FOLR1; the disease is ovarian carcinoma.